ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
46 announcements with these filters
Torrent Pharmaceuticals partially redeemed Rs.100 Crore of its unlisted secured NCDs on 09-11-2026, leaving Rs.300 Crore outstanding. This is a debt servicing event, not compliance paperwork.
Torrent Pharma received a ₹3.12 Crore GST penalty order for pre-acquisition JB Chemicals periods. The company will appeal and expects no material impact.
Torrent Pharmaceuticals disclosed that its RTA, KFin Technologies, is moving its corporate office effective December 1, 2026. Investors should update their records with the new address.
Revenue grew 51% following the JB Chemicals merger, but underlying business shows integration headwinds.
Torrent Pharmaceuticals filed its security cover certificate as on 30-Sep-26 for listed NCDs, showing 141% market-value cover. Secured debt covered by the certificate stands at Rs 11,578.42 Crore.
Torrent Pharmaceuticals Ltd reported revenue from operations of ₹4,979 Cr (+50.8% YoY) and net profit of ₹534 Cr (-9.6% YoY) for Q2 FY27.
Torrent Pharmaceuticals' Executive Director, Amal Kelshikar, has resigned from his position effective October 16, 2026.
India Ratings affirmed Torrent Pharmaceuticals' existing credit ratings and revised the outlook to positive. The company's commercial paper rating was also affirmed and assigned.
Torrent Pharmaceuticals will hold a board meeting on 23-Oct-26 to consider standalone audited and consolidated unaudited financial results for the quarter and half-year ended 30-Sep-26.
Torrent Pharmaceuticals confirmed Chintan M. Trivedi as Company Secretary and Compliance Officer. KFin Technologies Limited remains the company's Registrar and Share Transfer Agent.
Torrent Pharmaceuticals increased its investment in Torrent Urja 27 Private Limited to ₹11.88 Crore. The company is acquiring a 26% stake for a captive solar-wind project.
Shareholders approved the appointment of Ms. Shanti Ekambaram as an Independent Director of Torrent Pharmaceuticals via Postal Ballot.
Torrent Pharmaceuticals Limited has been assigned an ESG rating of 70 by NSE Sustainability Ratings and Analytics Limited. This independent assessment follows SEBI's regulatory framework for ESG Rating Providers.
Torrent Pharmaceuticals issued a Postal Ballot notice to shareholders for the appointment of Shanti Ekambaram as an Independent Director. Voting concludes on September 6, 2026.
Torrent Pharma delivered strong Q1 performance with revenues up 55% following the JB Chemicals merger completion. EBITDA margins jumped to 33.8% driven by accelerated cost synergies.
Torrent Pharmaceuticals submitted a statement under Regulation 52(7) & (7A) regarding the utilization of issue proceeds for the quarter ended June 30, 2026.
Torrent Pharmaceuticals Ltd reported revenue from operations of ₹4,921 Cr (+54.8% YoY) and net profit of ₹566 Cr (+3.3% YoY) for Q1 FY27.
Torrent Pharmaceuticals appointed Shanti Ekambaram as an Additional Independent Director. The appointment is for a three-year term effective July 30, 2026.
Torrent Pharmaceuticals allotted 4,19,22,416 equity shares to J.B. Chemicals shareholders. This allocation follows a Scheme of Amalgamation sanctioned by the NCLT.
Torrent Pharmaceuticals announced the voluntary dissolution of its Philippines-based subsidiary, Curatio Inc. The entity contributed Rs 1.3 Crore to the consolidated net worth.
Torrent Pharmaceuticals received an ESG rating of 66 and a Core ESG rating of 74 from Crisil. These ratings assess the company's environmental, social, and governance performance.
Torrent Pharmaceuticals will hold a Board Meeting on July 30, 2026. The meeting will consider financial results for the quarter ended June 30, 2026.
Torrent Pharmaceuticals initiated a voluntary recall for select batches of Semalix Injection Disposable Pens. The precautionary action follows a technical evaluation recall by manufacturer Dr. Reddy's.
Torrent Pharma announced NCLT's final order sanctioning its amalgamation with J.B. Chemicals. The scheme will become effective after filing with the Registrar of Companies.
Torrent Pharmaceuticals filed a security cover certificate for its non-convertible debentures. The certificate confirms a standalone security cover of 0.33 times book value.
Torrent Pharmaceuticals is valuing key brands at Rs. 16,374.09 Crore to raise funds via NCDs. The valuation includes brands like Nexpro, Chymoral, Rozucor, and Veloz.
Torrent Pharmaceuticals scheduled its 53rd Annual General Meeting for June 23, 2026. Key agenda items include adopting FY26 financial statements, confirming dividends, and re-appointing Director Samir Mehta.
Torrent Pharmaceuticals submitted its Business Responsibility and Sustainability Report for FY 2025-26. This routine filing outlines the company's ESG performance and strategic sustainability initiatives.
Torrent Pharmaceuticals submitted its Integrated Annual Report for FY 2025-26. The document includes the 53rd AGM notice and details regarding remote e-voting procedures.
Torrent Pharma Q4 FY26 revenue rose 42% to ₹4,197cr, driven by JB Pharma consolidation. Combined EBITDA margin stood at 32.3%, with focus on Semaglutide ramp-up in India and synergy execution.